Is Syngene International a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Syngene International Ltd is a good quality company .

Is Syngene International undervalued or overvalued?

The key valuation ratios of Syngene International Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Syngene International share price return in the past 10 years?

Data is not available for this company

Is Syngene International a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Syngene International Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Syngene International?

The latest standalone P/E ratio of Syngene International as of 20-Dec-2024 is 73.90.

What is the P/B ratio of Syngene International?

The latest standalone P/B ratio of Syngene International as of 20-Dec-2024 is 7.87.

Syngene International Ltd - Stock Valuation and Financial Performance

Name: Syngene International
Brand: Syngene International

BSE: 539268 | NSE: SYNGENE | Business Support | Small Cap

Place order

Syngene Internation. Share Price

₹844.65 -5.05 -0.59%
as on 20-Dec'24 16:59

10 Year X-Ray of Syngene Internation.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	23.3%	19.9%	17.6%	16.7%	16.9%	19.6%	15.4%	13.2%	15.6%	13.8%	-
Value Creation Index ⓘ	1.1	0.5	0.3	0.2	0.3	0.5	0.4	0.2	0.4	0.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	860	1,107	1,201	1,423	1,826	2,012	2,179	2,601	3,194	3,203	3,204
Sales YoY Gr.	-	28.7%	8.5%	18.5%	28.3%	10.2%	8.3%	19.4%	22.8%	0.3%	-
Adj EPS ⓘ	4.7	6.3	6.8	6	8.2	8.7	9.3	9.3	12.5	12.6	11.4
YoY Gr.	-	35.3%	7%	-11.7%	37.5%	6.3%	5.8%	0.9%	33.6%	1%	-
BVPS (₹) ⓘ	20.9	25.2	34.7	42.3	48.5	53.4	68.5	80	88.6	103.8	107.3
Adj Net Profit ⓘ	186	253	271	239	329	350	370	374	500	506	460
Cash Flow from Ops. ⓘ	18.5	308	398	446	630	677	698	582	838	913	-
Debt/CF from Ops. ⓘ	8.4	2.9	2	1.8	1.3	1	1.1	1.4	0.7	0.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	15.7%	11.9%	13.7%	0.3%
Adj EPS ⓘ	11.6%	8.9%	10.8%	1%
BVPSⓘ	19.5%	16.5%	14.9%	17.2%
Share Price	-	22.1%	13.2%	23.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	24.8	27.1	22.2	15.3	17.8	16.9	14.8	12.2	14.5	13	10.8
Op. Profit Mgn % ⓘ	34.6	36	32	28	29.4	29.9	30.2	28.4	30.8	29.3	27.4
Net Profit Mgn % ⓘ	21.7	22.9	22.6	16.8	18	17.4	17	14.4	15.7	15.8	14.4
Debt to Equity ⓘ	0.2	0.9	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0	0
Working Cap Days ⓘ	182	168	171	188	161	139	146	156	149	151	96
Cash Conv. Cycle ⓘ	24	37	31	20	14	18	29	42	47	44	43

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 13.70%

Net Profit is growing at healthy rate in last 3 years 10.82%

Return on Equity has declined versus last 3 years average to 10.80%

Sales growth is not so good in last 4 quarters at -3.00%

Latest Financials - Syngene International Ltd.

	Standalone	Consolidated
TTM EPS (₹)	11.4	12
TTM Sales (₹ Cr.)	3,204	3,451
BVPS (₹.) ⓘ	107.3	109.2
Reserves (₹ Cr.) ⓘ	3,943	3,993
P/BV ⓘ	7.87	7.74
PE ⓘ	73.90	70.55

From the Market
52 Week Low / High (₹)	608.00 / 960.00
All Time Low / High (₹)	147.50 / 960.00
Market Cap (₹ Cr.)	34,000
Equity (₹ Cr.)	402.5
Face Value (₹)	10
Industry PE ⓘ	53.6

Management X-Ray of Syngene Internation.:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Syngene Internation.

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Syngene Internation.

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	860	1,107	1,201	1,423	1,826	2,012	2,179	2,601	3,194	3,203
Operating Expenses ⓘ	579	727	816	1,033	1,291	1,410	1,528	1,864	2,261	2,324
Manufacturing Costs	298	375	407	497	632	668	739	978	1,148	1,085
Material Costs	-10	-4	1	-14	26	1	-25	-22	-42	57
Employee Cost	202	249	309	377	465	572	642	698	812	761
Other Costs ⓘ	89	107	100	173	167	169	173	209	343	421
Operating Profit ⓘ	281	380	385	390	535	602	651	738	933	879
Operating Profit Margin (%)	32.7%	34.4%	32.0%	27.4%	29.3%	29.9%	29.9%	28.4%	29.2%	27.4%
Other Income ⓘ	12	6	94	136	76	96	83	108	73	88
Interest ⓘ	8	8	18	23	32	35	28	24	45	30
Depreciation ⓘ	81	97	114	131	164	219	275	310	359	369
Exceptional Items ⓘ	0	0	0	0	0	71	35	-31	0	-11
Profit Before Tax ⓘ	204	281	347	372	414	516	467	482	601	557
Tax ⓘ	29	40	59	67	84	104	64	88	128	91
Profit After Tax	175	241	287	305	331	412	404	394	473	467
PAT Margin (%)	20.4%	21.8%	23.9%	21.4%	18.1%	20.5%	18.5%	15.1%	14.8%	14.6%
Adjusted EPS (₹)	4.4	6.0	7.2	7.6	8.3	10.3	10.1	9.8	11.8	11.6
Dividend Payout Ratio (%)	239%	8%	7%	7%	3%	0%	0%	10%	11%	11%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	833	1,006	1,388	1,692	1,939	2,135	2,741	3,205	3,556	4,174
Share Capital ⓘ	199	200	200	200	200	400	400	401	401	402
Reserves ⓘ	634	806	1,188	1,492	1,739	1,735	2,341	2,804	3,155	3,772
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	155	891	787	664	537	309	772	790	575	142
Long Term Debt	19	725	690	586	347	0	512	532	489	100
Short Term Debt	136	166	97	78	191	309	260	258	86	42
Trade Payables	69	74	103	203	224	223	239	235	260	254
Others Liabilities ⓘ	364	313	434	557	911	1,372	1,036	1,266	1,377	1,214
Total Liabilities ⓘ	1,422	2,284	2,711	3,116	3,611	4,039	4,789	5,496	5,768	5,784
Fixed Assets
Gross Block	938	1,111	1,332	1,661	2,121	2,967	3,404	3,883	3,994	4,294
Accumulated Depreciation	435	531	522	630	784	984	1,241	1,528	1,782	2,017
Net Fixed Assetsⓘ	503	580	810	1,030	1,337	1,984	2,163	2,354	2,212	2,277
CWIP ⓘ	105	237	175	155	274	234	237	346	126	760
Investmentsⓘ	146	277	540	158	716	777	702	1,034	941	928
Inventories	38	38	32	86	43	25	60	179	333	234
Trade Receivables	180	185	199	267	339	398	474	508	484	428
Cash Equivalents	116	720	527	967	435	280	638	515	509	528
Others Assetsⓘ	333	247	427	453	467	341	514	558	1,163	630
Total Assets ⓘ	1,422	2,284	2,711	3,116	3,611	4,039	4,789	5,496	5,768	5,784

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	19	308	398	446	630	677	698	582	838	913
PBT ⓘ	204	281	347	372	414	516	467	482	601	557
Adjustment ⓘ	73	93	89	181	129	223	279	381	375	289
Changes in Working Capital ⓘ	-216	-26	37	-27	182	45	35	-177	-4	165
Tax Paid ⓘ	-42	-40	-75	-81	-96	-106	-83	-104	-134	-98
Cash Flow From Investing Activity ⓘ	12	-751	-469	-350	-647	-428	-628	-612	-688	-384
Capex	-204	-294	-306	-364	-583	-643	-447	-476	-533	-346
Net Investments	206	-463	-218	-4	-119	126	-244	-162	-209	-119
Others ⓘ	10	6	55	18	55	89	62	26	54	81
Cash Flow From Financing Activityⓘ	-10	716	-81	-79	-72	-226	58	-31	-340	-536
Net Proceeds from Shares ⓘ	137	2	2	5	2	1	1	0	0	0
Net Proceeds from Borrowing ⓘ	19	707	0	-19	-129	-268	134	0	0	-390
Interest Paid ⓘ	-8	-1	-18	-23	-30	-35	-28	-18	-34	-18
Dividend Paid ⓘ	-114	-20	0	-24	-24	-24	0	0	-40	-50
Others ⓘ	-45	28	-66	-17	109	100	-49	-14	-266	-77
Net Cash Flow ⓘ	20	273	-152	17	-89	24	128	-61	-190	-6

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	23.55	26.19	24	19.81	18.21	20.2	16.56	13.24	13.99	12.07
ROCE (%)	23.31	19.85	17.6	16.7	16.94	19.57	15.35	13.19	15.61	13.76
Asset Turnover Ratio	0.66	0.6	0.48	0.49	0.54	0.53	0.49	0.51	0.57	0.56
PAT to CFO Conversion(x)	0.11	1.28	1.39	1.46	1.9	1.64	1.73	1.48	1.77	1.96
Working Capital Days
Receivable Days	58	60	58	60	61	67	73	69	57	52
Inventory Days	11	13	11	15	13	6	7	17	29	32
Payable Days	-2,583	-5,956	0	-4,135	2,997	0	-3,345	-4,008	-2,154	1,659

Syngene International Ltd Stock News

Syngene International Ltd FAQs

What is the share price of Syngene Internation.?

Company share prices are keep on changing according to the market conditions. The closing price of Syngene Internation. on 20-Dec-2024 16:59 is ₹844.6.

What is the market cap of Syngene Internation.?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Syngene Internation. stood at ₹34,000.3.

What is the P/E ratio of Syngene Internation.?

The latest P/E ratio of Syngene Internation. as of 20-Dec-2024 16:59 is 73.90.

What is the P/B ratio of Syngene Internation.?

The latest P/B ratio of Syngene Internation. as of 20-Dec-2024 16:59 is 7.87.

What is the 52-week high and low of Syngene Internation.?

The 52-week high of Syngene Internation. is ₹960.0 and the 52-week low is ₹608.0.

What is the TTM revenue of Syngene Internation.?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Syngene Internation. is ₹3,204 ( Cr.) .

About Syngene International Ltd

Syngene International, incorporated in 1993, is an internationally reputed contract research and manufacturing organization, which supports R&D programs from lead generation to clinical supplies. The company’s multi-disciplinary skills in integrated drug discovery and development include capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services. The company has state-of-the-art research facilities certified with ISO 9001:2008, ISO 14001:2004, and OHSAS 18001:2007. The company’s animal facilities are GLP certified by the Indian authorities and AAALAC accredited. The company has successfully offered these services to many clients including start-up companies, large pharma/ biotech, agrochemical, chemical, nutrition and animal health companies in the USA, Europe and the Asia Pacific including Japan and Australia. Syngene has a strong corporate governance framework with a focus on client satisfaction, quality, safety, ethics and integrity. The company’s ability to deliver significant value to its customers by leveraging its scientific skills, global mindset and India’s cost competitiveness differentiates it as one of the most preferred partners.

Business area of the company

The company is engaged in providing contract research and manufacturing services from lead generation to clinical supplies to pharmaceutical and biotechnology companies worldwide.

Services

Discovery Chemistry
Discovery Biology
Safety Assessment
Large Molecule Development
Chemical Development
Formulation Development
Stability Studies
Polymer Research
Integrated Discovery & Development
Clinical Development Services
Bioinformatics
Antibody Drug Conjugates
Oligonucleotide Synthesis

Awards

2000-01: Certificate of Excellence for Export Achievement - Under 100% EOU Scheme in Karnataka.
2001-02: Certificate of Excellence for Export Achievement - Under 100% EOU Scheme in Karnataka.
2001-02: Top Exporter Sector - Biotechnology; 100% EOUs in Karnataka; Ptd by Cochin Special Economic Zone, Govt of India, Ministry of Commerce & Industry.
2005: BioSpectrum Bio Services Company of the Year.
2007: BioSpectrum Bio Services Company of the Year.
2008: 'Bangalore Bio' Bio Excellence Award - Biotech Services Sector.
2008: BioSpectrum Bio Services Company of the Year.
2009: 'Bangalore Bio' Bio Excellence Award - Biotech Services Sector.
2009: Best Bioservices Company of the Year- by Biospectrum.
2011: CIO100 Award.
2011: 'Workplace Assessment Conditions (WCA) Achievement Award' by Intertek.
2011: 'Sliver EDGE' Award - Enterprise Driving Growth & Excellence Through IT.
2012: CIO100 Award for highest level of operational and strategic excellence in information technology.
2013: ABLE (Association of Biotechnology Led Enterprises) - Tenth Anniversary Award for ‘Outstanding contribution to Bioservices’.
2013: Diamond Sponsor-Recognation by the Association of Scientists of Indian Origin of the Society of Toxicology.
2014: 'Sliver EDGE' Award - Enterprise Driving Growth & Excellence Through IT for ‘Comprehensive SAP Implementation’.
2014: EHS best practices award by CII.
2014: SAP Ace Award for special recognition for complex SAP implementation.
2014: Level I Laboratory certification issued by the NGSP to Clinigene International Limited.
2014: SAP ACE Award 2014 won by Syngene RISE team.
2015: Organisation with Innovative HR Practices Award - At the 14th Annual Asia Pacific HRM Congress 2015.
2015: CIO100 Award 2015 - The Versatile Honoree Award & The CIO 100 Networking Pioneer Special Award.
2015: Bangalore India Bio - Bio Excellence Award for outstanding contribution to the Biotech services sector.
2016: Dynamic Enterprise of the Year 2016 - At the 9th Annual Pharmaceutical Leadership Summit & Pharma Leaders Business Leadership Awards 2016- in recognition for its contribution to the field of Research and Development for the Life Science Industry.
2016: CII Award - Won first place in the Office/Software/Service Sector.
2016: CII Award- Four Star Rating on Environment Health & Safety Management System.
2017: Best Contract Research Organisation (CRO) Provider - Runner-up Award - At The 4th Annual World ADC Awards 2017.
2017: Bio Services Excellence Award 2017 - Bangalore Tech Summit.
2018: Bio-Excellence Award 2018 - At Bengaluru Tech Summit, Bengaluru.
2018: Best Bioprocessing Excellence Award 2018 - At 5th Biologics Manufacturing Asia, Singapore.
2018: Healthcare Company of the Year 2018- At the 7th Annual VCCircle Awards 2018, Mumbai.
2018: HR Excellence Award 2018 'For Best Talent Management Strategy' - At the HR Talent Management Leadership Awards (World HRD Congress), Mumbai.
2019: Best Employer Brand 2019 by the Employer Branding Institute, World HRD Congress at the 14th edition of the awards for robust and effective HR and people management system.
2019: India Pharma Award 2019 - For “Excellence in Contract Research and Manufacturing Services” at CPhI & P-MEC India Expo.
2019: Utthama Suraksha Puraskar 2019 - (Pharma and Chemical Manufacturing Category) by National Safety Council of India (NSCI). Leadership Awards.
2019: CMO Leadership Awards- Presented by Life Science Leader Magazine in New York.
2019: FICCI CSR Award for Environmental Sustainability - At the 17th Edition of the awards in New Delhi.
2019: Safe Workplace Champion Award - At the 8th Manufacturing Supply Chain Summit and Awards.
2019: Best Leadership Development Program for Middle Management Award - At the 6th Global Training and Development Leadership Awards.

Milestones

1994: Initiated operations as a CRO with services in chemistry and biology.
1998: Granted 100% Export Oriented Unit (EOU) status by the Government of India.
1999: First operational expansion in R&D by way of expansion of lab space to over 23,000 sq. ft.
2000: Clinigene International Limited (CIL) was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies.
2001: Forayed into chemical development with a dedicated manufacturing facility.
2003: Moved to Biocon SEZ, a 90-acre biopharmaceutical SEZ with operations spread over 65,000 sq. ft.
2007: Bristol-Myers Squibb and the Company signed the first long-term contract to set up its first dedicated R&D Center.
2007: Expansion of research facilities at Biocon SEZ to 148,000 sq. ft.
2007: Crossed an annual turnover of over Rs 1,000 million in Financial Year 2007.
2009: Dupont Crop Protection and the Company extended a partnership for R&D services.
2009: Expansion of manufacturing services with a new plant which is cGMP compliant.
2009: Initiated operations in safety assessment and large molecules development services.
2010: Acceptance of the clinical and bio-analytical facilities of Clinigene International Limited by the Department of Health and Human Services, FDA.
2010: Initiated operations in formulation development.
2011: Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer.
2012: Abbott and Syngene collaborated to establish Abbott's nutrition research and development center in India and its second dedicated R&D center.
2012: Certification of clinical facilities by ANVISA.
2012: Acquired 100% stake in Clinigene International Limited from Biocon.
2013: Crossed an annual turnover of over Rs 5,000 million in Financial Year 2013.
2013: Crossed an annual turnover of over Rs 5,000 million in Financial Year 2013.
2013: Acceptance of its control testing laboratory by the Department of Health & Human Services, FDA.
2014: Bristol Myers Squibb and Syngene extend collaboration for its dedicated R&D center until 2020.
2014: Acceptance of manufacturing facility by the Department of Health & Human Services, FDA.
2014: Established a 75,000 sq.ft center to provide stability and analytical services.
2015: Syngene listed on BSE (Bombay Stock Exchange) & NSE (National Stock Exchange) of India
2015: Clinigene International Limited amalgamated with Syngene.
2016: Acquisition of Strand Life Sciences’ Systems Biology and Pharma Services Practice Assets: Expansion into Bioinformatics & NGS Services.
2016: Amgen Inc. collaborated with Syngene to establish the ‘Syngene Amgen Research and Development Center (SARC)’, its fourth dedicated R&D center.
2016: Crossed an annual turnover of Rs 10,000 Million.
2017: Strategic collaboration with Zoetis to develop and manufacture animal medicines.
2017: Herbalife Nutrition collaborated with Syngene to establish its first nutrition research & development center in India.
2017: Broadening of Research Collaboration with Amgen Inc. Expands Dedicated R&D Center.
2017: Expansion of Bristol-Myers Squibb's ongoing research collaboration with Syngene & the collaboration extended until 2026.
2018: Signed R&D agreement with GSK to advance drug discovery in multiple therapeutic areas.
2018: Received PMDA Accreditation.
2018: Syngene announces partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services.
2018: Syngene expands collaboration with Baxter until 2024.
2019: Signed an agreement with Biotechnology Industry Research Assistance Council (BIRAC), a Government of India undertaking, for setting up Center for Advanced Protein Studies (CAPS).
2019: cGMP approval from Ministry of Health, Russian Federation for the drug product manufacturing facility, stability center and quality function.
2020: Commenced Phase I operations at Hyderabad.
2020: GLP certification for Viral Testing Facility approval from NGCMA (India’s first and only GLP-certified viral clearance study service provider).
2020: COVID-19: Setting up of RT-PCR testing center.
2020: Successfully completed unannounced US FDA inspection for Bio-analytical studies.
2020: Extended biologics discovery and preclinical research capabilities in CAR -T cell therapy.
2020: Mangalore API facility completes construction phase and moves into qualification phase; executed 1st order.